NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled RoAD proof-of-concept study of PrimeC ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE